Affiliation:
1. Dartmouth Cancer Center, Dartmouth Hitchcock Medical Center , Lebanon, NH , USA
2. Ascension St. Vincent’s Riverside , Jacksonville, FL , USA
Abstract
Abstract
Purpose
Peripherally acting μ-opioid receptor antagonists (PAMORAs) are indicated to treat laxative-refractory opioid-induced constipation (OIC). While several PAMORAs exist, no head-to-head comparative data are available. This study evaluated the efficacy, safety, and cost of oral naloxegol vs subcutaneous methylnaltrexone for OIC in the hospital.
Methods
In this multicenter retrospective chart review, patients who received oral naloxegol or subcutaneous methylnaltrexone as an inpatient were included if they were at least 18 years old, were still admitted to the hospital 48 hours after the first PAMORA dose, and either had an outpatient opioid prescription or received at least 30 morphine milligram equivalents in the 24 hours before the first PAMORA dose. The primary outcome was achievement of a bowel movement (BM) within 48 hours of the first dose. Secondary outcomes included a BM in 24 hours, time to the first BM, antimotility agent use, PAMORA cost per patient, and use of a second PAMORA due to failure of the first agent.
Results
A total of 330 patients were included with 2:1 allocation (220 patients receiving methylnaltrexone vs 110 patients receiving naloxegol). Baseline characteristics were similar between the groups, except for body mass index and weight. Naloxegol met a prespecified noninferiority margin of 15% in production of a BM within 48 hours (risk difference, –4.6%; 90% confidence interval, –13.6% to 4.5%; P = 0.028). Achievement of a BM within 24 hours and time to first BM were also noninferior. Antimotility agent use was higher with naloxegol, naloxegol cost $193.16 less per patient, and 2 patients switched from naloxegol to methylnaltrexone.
Conclusion
Oral naloxegol may be an effective, cost-efficient alternative to subcutaneous methylnaltrexone for treatment of OIC in the hospital setting.
Publisher
Oxford University Press (OUP)
Subject
Health Policy,Pharmacology
Reference14 articles.
1. Prevalence of prescription pain medication use among adults: United States, 2015-2018;Hales;NCHS Data Brief,2020
2. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities;Nelson;Therap Adv Gastroenterol,2015
3. Opioid-induced constipation;Argoff;Clin J Pain,2020
4. Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain;Wan;Am Health Drug Benefits,2015
5. American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation;Crockett;Gastroenterology,2019
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献